0
Abstract: Poster Presentations |

A PROSPECTIVE STUDY FOR EVALUATING THE EFFECT OF SILYMARIN ON HEPATIC FUNCTIONS IN TUBERCULAR PATIENTS RECEIVING DOTS FREE TO VIEW

Sharad Bedi, MBBS*; Ashok Goel, MD; Nirmal Chand, MD; Jaswant Rai, MD
Author and Funding Information

Government Medical College, Amritsar, Punjab, India


Chest


Chest. 2009;136(4_MeetingAbstracts):74S. doi:10.1378/chest.136.4_MeetingAbstracts.74S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Tuberculosis is a chronic infectious, multisystem disorder and is affecting millions globally. ATT used under DOTS has hepatotoxic potential. Silymarin, an indigenous herb is used in various traditional formulations for treating hepatic disorders. So the present study was conducted to evaluate the effect of silymarin on hepatic functions in tubercular patients receiving DOTS.

METHODS:  Present study was prospective, double-blind, randomized, placebo-controlled. It comprised two groups of 50 tubercular patients each receiving standard therapy DOTS as per category of the patient. One group received silymarin 140 mg thrice daily and second group received identical placebo as add on therapy to DOTS for 8 weeks. SGOT, SGPT, ALP and serum bilirubin of both the groups were measured at 0 week, 4 weeks, 8 weeks and were analyzed by student's t-test.

RESULTS:  Baseline investigations of SGOT, SGPT, ALP and serum bilirubin in both the groups were comparable ( p > 0.05). Non-significant mean increase in SGOT (7.2%), SGPT (6%), ALP (5.9%) levels and significant mean increase in bilirubin levels (17.4%) was observed in silymarin arm as compared to significant increase in SGOT (25.6%), SGPT (28%), ALP (11.7%) levels and extremely significant mean increase in bilirubin levels (43.6%) in the placebo arm. In the silymarin arm, decrease in SGOT levels was seen in 6% of the patients, decrease in SGPT levels was seen in 4% of the patients and decrease in ALP levels was seen in 6% of the patients from 0 week (baseline values) whereas none of the patients showed decrease in levels from baseline in the placebo arm.

CONCLUSION:  Silymarin has been found to suppress the deterioration in the hepatic functions associated with use of ATT in patients receiving DOTS; and found to be hepatoprotective.

CLINICAL IMPLICATIONS:  Silymarin can be recommended as an adjuvant to DOTS in tubercular patients since it attenuates the hepatotoxicity caused by ATT.

DISCLOSURE:  Sharad Bedi, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, November 3, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543